- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07613112
Longitudinal Natural History Protocol for PRKN- and PINK1-Linked PD
Longitudinal Natural History Protocol for PRKN- and PINK1-linked PD
Background:
Parkinson s disease is a neurologic disorder that affects movement. Its cause is unknown, and it usually begins later in life. Gene changes (PRKN and PINK1) can also cause rare types of Parkinson s disease that start at a young age. Researchers want to conduct a natural history study to learn more about how genes play a role in Parkinson s disease.
Objective:
To collect data and biological samples from people with different types of Parkinson s disease.
Eligibility:
People aged 18 to 80 years with either Parkinson s disease or PRKN- and PINK1-linked Parkinson s disease. Healthy volunteers are also needed.
Design:
Participants will have 6 clinic visits over 5 years. Each visit may take 1 to 3 days.
During each visit:
Participants will have a physical exam. The exam will be videotaped.
They will answer questions about their movement, thinking, mood, and sense of smell. The extent of any symptoms of Parkinson s disease will be evaluated: Participants movements may be assessed with a finger tapping test. They may be asked to scratch and sniff different scented strips to identify odors.
They will wear motion sensors on their arms, legs, chest, and back at the clinic. They will wear motion sensor devices on their wrists at home for 1 week.
Blood and urine samples will be collected.
Other tests are optional:
Magnetic resonance imaging (MRI) scan of the brain. Participants will lie on a table that slides into a tube.
Lumbar puncture (spinal tap). A thin needle will be inserted into their lower back to draw out a sample of the fluid around their spinal cord.
Muscle biopsy. A small sample of tissue will be taken from the leg.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
Study Description:
This is a longitudinal, observational study that aims to assess progression of clinical features, imaging, and biologic markers of PD in study participants with and without manifest PD who are bi-allelic or mono-allelic carriers of pathogenic variants in the recessively inherited genes PRKN and PINK1 that represent prototypes of mitochondrial- associated PD.
Objectives:
Primary Objective: To characterize the natural history of motor symptoms in PRKN- and PINK1-linked PD.
Secondary Objectives: To comprehensively characterize other clinical features of PRKN- and PINK1-linked PD over time
Tertiary Objectives:
- To characterize structural brain changes over time
- To identify molecular signatures that differ between PRKN and PINK1-associated PD, non-manifesting mutation carriers, wildtype PD, and healthy controls.
- To generate a repository of longitudinal data and samples for future studies aimed at developing targeted therapies.
- To characterize in-home assessment of movements
- To evaluate for mitochondrial changes in the muscle
Endpoints:
Primary Endpoint: Annual change in MDS Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III
Secondary Endpoints:
- Annual change in MDS-UPDRS parts I, II, IV
- Annual change in Montreal Cognitive Assessment (MoCA)
- Annual change in Timed up and go (TUG)
- Annual change in 10-meter walk
- Annual change in 360 degree turn
- Annual change in Unified Dyskinesia Rating Scale (UDysRS)
- Annual change in University of Pennsylvania Smell Identification Test (UPSIT)
- Annual change in REM-Sleep-Behavior Disorder Screening Questionnaire (RBD-SQ)
- Annual change in Questionnaire for Impulsive-Compulsive Disorders (QUIP)
- Annual change in Epworth Sleepiness Scale (ESS)
- Annual change in Geriatric Depression Scale (GDS)
- Annual change in State-Trait Anxiety Inventory (STAI)
- Annual change in Scales for Outcomes in Parkinson s Disease - Autonomic Dysfunction (SCOPA AUT)
- Annual change in 39-item Parkinson s Disease Questionnaire (PDQ-39)- quality of life measurement
- Annual change in Schwab and England Activities of Daily Living (SE-ADL) scale
- Annual change in Hoehn and Yahr scale assessment Tertiary endpoints:
- Annual change of brain MRI measurement of overall brain, striatum and substantia nigra volumes
- Annual change of brain MRI measurement of iron deposition
- Annual change in studies from blood
- Annual change in studies from CSF
- Annual change in studies from urine
- Annual change in Wearable Accelerometry data
- Evidence of mitochondrial cytopathy on muscle biopsy
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Debra J Ehrlich, M.D.
- Numéro de téléphone: (301) 443-7888
- E-mail: debra.ehrlich@nih.gov
Sauvegarde des contacts de l'étude
- Nom: Oday K Halhouli, M.D.
- Numéro de téléphone: (301) 402-7969
- E-mail: oday.halhouli@nih.gov
Lieux d'étude
-
-
Maryland
-
Bethesda, Maryland, États-Unis, 20892
- National Institutes of Health Clinical Center
-
Contact:
- NIH Clinical Center Office of Patient Recruitment (OPR)
- Numéro de téléphone: TTY dial 711 800-411-1222
- E-mail: ccopr@nih.gov
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Méthode d'échantillonnage
Population étudiée
La description
- INCLUSION CRITERIA:
To be eligible to participate in this study, an individual must meet all of the following criteria:
All participants:
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Male or female between the ages of 18-80 years old
- Ability of subject to understand and the willingness to sign an informed consent document
- Ability of subject to travel to the NIH Clinical Center
Additional inclusion criteria for each cohort as below:
PD Mito Biallelic:
- Established clinical diagnosis of Parkinson s disease
- Two Pathogenic or likely pathogenic variants in PRKN or PINK1
PD Mito Monoallelic:
- Established clinical diagnosis of Parkinson s disease
- One Pathogenic or likely pathogenic variant in PRKN and/or PINK1
Idiopathic Parkinson s Disease (PD):
- Established clinical diagnosis of Parkinson s disease
- Etiology of PD is idiopathic/sporadic based on investigator determination
Non-manifesting mito:
- One or two pathogenic or likely pathogenic variant in PRKN and/or PINK1
- Lack of clinical diagnosis of Parkinson s disease
- Lack of current or clinically significant neurological disorder (based on investigator determination)
Healthy Volunteer
-Lack of current or clinically significant neurological disorder (based on investigator determination)
EXCLUSION CRITERIA:
An individual who meets any of the following criteria will be excluded from participation in this study:
All participants:
- Symptomatic PD syndromes due to drugs (e.g., metoclopramide, flunarizine, neuroleptics), metabolic disorders (e.g., Wilson s disease hypothyroidism), encephalitis, brain lesion, atypical parkinsonism, other monogenic forms of PD (e.g., GBA1, LRRK2, SNCA, VPS35, CHCHD2, DJ1, ATP13A2) other genetic disorders that may cause parkinsonism (e.g., spinocerebellar ataxia, X-linked dystonia parkinsonism)
- Pregnancy at time of study enrollment
- Any other reason that, in the opinion of the investigator, would render the participant unsuitable for study enrollment
- Unwilling to allow samples or data to be shared with other researchers or institutions.
- NIH staff or family members of study team members
Healthy Volunteer:
-Participants who become pregnant during the study will be withdrawn from further study procedures at the time pregnancy is identified.
Procedural Exclusions:
Subjects may still be enrolled if they cannot participate in certain procedures due to not meeting the inclusion requirements for that specific procedure. Subjects who meet exclusion criteria for procedures listed below may still undergo the procedure at a later time if the reason of exclusion is no longer present.
Brain MRI:
- Contraindications to MRI such as a contraindicated non-removable metal device (i.e., pacemaker, defibrillator, insulin pump, metal clips, non-removable jewelry)
- Pregnancy
Accelerometer:
-Non ambulatory
Lumbar puncture procedure:
- PT/PTT values that are prolonged greater than or equal to 3 seconds from the upper limit of normal (including treatment with oral and parenteral anticoagulants)
- INR greater than 1.4, thrombocytopenia (<70,000), or abnormal bleeding time or platelet dysfunction
- History of a bleeding disorder
- Use of anticoagulants or antiplatelets
- Pregnancy
- History of headache requiring blood patch after a previous LP
Needle muscle biopsy:
- PT/PTT values that are prolonged greater than or equal to 3 seconds from the upper limit of normal (including treatment with oral and parenteral anticoagulants)
- INR greater than 1.4, thrombocytopenia (<70,000), or abnormal bleeding time or platelet dysfunction
- History of a bleeding disorder
- Use of anticoagulants or antiplatelets
- Pregnancy
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
|---|
|
Healthy controls
Lack of current or clinically significant neurological disorder (based on investigator determination).
|
|
Non-manifesting mito
participants who carry one or two pathogenic variants in PRKN and/or PINK1 but do not have a diagnosis of PD
|
|
PD idiopathic
PD participants with idiopathic PD
|
|
PD mito - monoallelic
Monoallelic: PD participants carrying one pathogenic mono-allelic variant in PRKN and/or PINK1
|
|
PD mito - biallelic
Biallelic: PD participants carrying two pathogenic variants in PRKN or PINK1
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Estimation of progression of motor symptoms across cohorts
Délai: When final patient completes their last visit
|
Measured by annual change in MDS Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III
|
When final patient completes their last visit
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Annual change in MDS-UPDRS parts I, II, IV
Délai: When final patient completes their last visit
|
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
|
When final patient completes their last visit
|
|
Annual change in Montreal Cognitive Assessment (MoCA)
Délai: When final patient completes their last visit
|
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
|
When final patient completes their last visit
|
|
Annual change in Timed up and go (TUG)
Délai: When final patient completes their last visit
|
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
|
When final patient completes their last visit
|
|
Annual change in 10-meter walk
Délai: When final patient completes their last visit
|
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
|
When final patient completes their last visit
|
|
Annual change in 360 degree turn
Délai: When final patient completes their last visit
|
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
|
When final patient completes their last visit
|
|
Annual change in Unified Dyskinesia Rating Scale (UDysRS)
Délai: When final patient completes their last visit
|
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
|
When final patient completes their last visit
|
|
Annual change in University of Pennsylvania Smell Identification Test (UPSIT)
Délai: When final patient completes their last visit
|
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
|
When final patient completes their last visit
|
|
Annual change in REM-Sleep-Behavior Disorder Screening Questionnaire (RBD-SQ)
Délai: When final patient completes their last visit
|
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
|
When final patient completes their last visit
|
|
Annual change in Questionnaire for Impulsive-Compulsive Disorders (QUIP)
Délai: When final patient completes their last visit
|
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
|
When final patient completes their last visit
|
|
Annual change in Epworth Sleepiness Scale (ESS)
Délai: When final patient completes their last visit
|
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
|
When final patient completes their last visit
|
|
Annual change in Geriatric Depression Scale (GDS)
Délai: When final patient completes their last visit
|
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
|
When final patient completes their last visit
|
|
Annual change in State-Trait Anxiety Inventory (STAI)
Délai: When final patient completes their last visit
|
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
|
When final patient completes their last visit
|
|
Annual change in Scales for Outcomes in Parkinson's Disease - Autonomic Dysfunction (SCOPA AUT)
Délai: When final patient completes their last visit
|
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
|
When final patient completes their last visit
|
|
Annual change in 39-item Parkinson's Disease Questionnaire (PDQ-39) - quality of life measurement
Délai: When final patient completes their last visit
|
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
|
When final patient completes their last visit
|
|
Annual change in Schwab and England Activities of Daily Living (SE-ADL) scale
Délai: When final patient completes their last visit
|
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
|
When final patient completes their last visit
|
|
Annual change in Hoehn and Yahr scale assessment
Délai: When final patient completes their last visit
|
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
|
When final patient completes their last visit
|
Collaborateurs et enquêteurs
Les enquêteurs
- Chercheur principal: Debra J Ehrlich, M.D., National Institute of Neurological Disorders and Stroke (NINDS)
Publications et liens utiles
Liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur PARKINSON DIS
-
Bezmialem Vakif UniversityRecrutementMaladie de Parkinson | Parkinson | Maladie de Parkinson (MP) | MALADIE DE PARKINSON (trouble) | La maladie de ParkinsonTurquie (Türkiye)
-
CND Life SciencesDigestive Disease Associates of CTRecrutementMaladie de Parkinson | Parkinson | MALADIE DE PARKINSON (trouble) | La maladie de ParkinsonÉtats-Unis
-
Neuron23 Inc.Roche Diagnostic Ltd.; Qiagen Manchester LimitedRecrutementMaladie de Parkinson | Parkinson | Maladie de Parkinson idiopathique | Maladie de Parkinson, idiopathique | Maladie de Parkinson précoce (PD précoce)États-Unis, Espagne, Israël, Pologne, Italie, Royaume-Uni
-
CND Life SciencesOregon Health and Science UniversityRecrutementMaladie de Parkinson | Parkinson | Maladie de Parkinson et parkinsonisme | MALADIE DE PARKINSON (trouble)États-Unis
-
University of LahoreComplété
-
ProgenaBiomeRetiréMaladie de Parkinson | Maladie de Parkinson avec démence | Syndrome de Parkinson-Démence | Maladie de Parkinson 2 | Maladie de Parkinson 3 | Maladie de Parkinson 4États-Unis
-
Duke UniversityMedical University of South Carolina; Massachusetts General Hospital; Mayo Clinic et autres collaborateursPas encore de recrutementMicrobiote intestinal | Microbiome intestinal | Maladie de Parkinson (MP) | MALADIE DE PARKINSON (trouble) | Maladie de Parkinson ProdromiqueÉtats-Unis
-
InvicroMerck Sharp & Dohme LLCRecrutementLa maladie de Parkinson | Maladie de Parkinson (MP) | Maladie de Parkinson (trouble)États-Unis
-
National Heart, Lung, and Blood Institute (NHLBI)ComplétéMaladie de Parkinson 6, début précoce | Maladie de Parkinson (autosomique récessive, début précoce) 7, humain | Maladie de Parkinson autosomique récessive, début précoce | Maladie de Parkinson, début précoce autosomique récessif, digénique, Pink1/Dj1États-Unis
-
Università degli Studi dell'InsubriaUniversidade Nova de Lisboa; Associazione Parkinson Insubria (AsPI), Section... et autres collaborateursRecrutementMaladie de Parkinson | Parkinson | Maladie de Parkinson, idiopathique | MALADIE DE PARKINSON (trouble)Italie